Journal: Journal of Korean Neurosurgical Society
Article Title: Comparative Evaluation of Imatinib and Nilotinib in a Streptozotocin-Induced Rat Model of Alzheimer’s Disease : Neuroprotective, Anti-inflammatory, and Cognitive Outcomes
doi: 10.3340/jkns.2025.0110
Figure Lengend Snippet: Cresyl violet staining of the CA1 and CA3 regions of the hippocampus (×40 magnification). A : CA1, control. Normal pyramidal neurons with well-organized and densely packed cellular architecture. B : CA3, control. Preserved neuronal morphology and normal pyramidal cell layer organization. C : CA1, ICV-STZ + saline. Reduced neuronal density and early neurodegenerative changes, including shrunken pyramidal neurons and pericellular spaces (arrows). D : CA3, ICV-STZ + saline. Marked neuronal loss, severe disruption of pyramidal layer organization, and presence of pyknotic neurons (arrows). E : CA1, ICV-STZ + imatinib. Increased neuronal count compared to the ICV-STZ group, with partial restoration of pyramidal neuron morphology. F : CA3, ICV-STZ + imatinib. Moderate improvement in neuronal density and morphology, although some degenerative changes persist. G : CA1, ICV-STZ + nilotinib. Increased neuronal density and improved cellular organization, approaching nearnormal morphology. H : CA3, ICV-STZ + nilotinib. Significant restoration of pyramidal layer structure with increased neuronal count and improved morphology. ICV-STZ : intracerebroventricular streptozotocin.
Article Snippet: Group 2 (n=8) received 60 mg/kg imatinib (Gleevec ® ; Novartis Pharmaceuticals, Basel, Switzerland) daily via oral gavage.
Techniques: Staining, Control, Saline, Disruption
